I'm more optimistic with Phase 3 severe/critical results than I was with Phase 2 Mild/Moderate. Two months ago I wrote -
There is no way that Leronlimab in the phase 2 trials didn't kick butt like always!
The only way you could get mediocre results would be if the trial participants in the placebo arm were truly mild and NEVER GOT WORSE throughout course of their illness. If the participants in the treatment arm were truly in need of the blocking of their CCR5 receptors to get better, THAT HAPPENED, no doubt!
No other drug out there can beat Leronlimab. It will become the standard of care among treatments, no doubt. It is just chemistry! If a patient has CCR5 receptors, Leronlimab will bind with them and the immune system will begin to reset to homeostasis.
Molecules don't think, they act. Dosage could effect how many receptors are blocked with Lero but, otherwise, the blocking is a done deal and the resulting benefits are then a matter of what a patient's body has to work with to set things straight.
Lero can't save everyone who gets it but it will NEVER NOT HELP those who get it. If the health results from taking Leronlimab aren't sterling, it is not Lero's fault.
Patterson knows this more than anyone else because he is observing things at the cellular and molecular scale. Those observing health results at more macro levels are looking at things in a diluted, obfuscated way. They may or may not see things so clearly. However, they will not see results any MORE clearly with any other drug.
Leronlimab WILL be the new standard of cure and it WILL set the bar very, very high, not just for COVID-19 but for many indications.
The most disappointing thing I heard on the ASM call was that available supply of Lero is still miserably small and supply is being postponed. This wouldn't have happened with participation in OWS but there may have been strings attached to that that Cytodyn didn't want. They charted their own course.
Perhaps England will be the route to better supply or at least financing help - who knows? The Second Wave will have the whole world screaming for supply IMO.
There is no way that Leronlimab in the phase 2 trials didn't kick butt like always!
The only way you could get mediocre results would be if the trial participants in the placebo arm were truly mild and NEVER GOT WORSE throughout course of their illness. If the participants in the treatment arm were truly in need of the blocking of their CCR5 receptors to get better, THAT HAPPENED, no doubt!
No other drug out there can beat Leronlimab. It will become the standard of care among treatments, no doubt. It is just chemistry! If a patient has CCR5 receptors, Leronlimab will bind with them and the immune system will begin to reset to homeostasis.
Molecules don't think, they act. Dosage could effect how many receptors are blocked with Lero but, otherwise, the blocking is a done deal and the resulting benefits are then a matter of what a patient's body has to work with to set things straight.
Lero can't save everyone who gets it but it will NEVER NOT HELP those who get it. If the health results from taking Leronlimab aren't sterling, it is not Lero's fault.
Patterson knows this more than anyone else because he is observing things at the cellular and molecular scale. Those observing health results at more macro levels are looking at things in a diluted, obfuscated way. They may or may not see things so clearly. However, they will not see results any MORE clearly with any other drug.
Leronlimab WILL be the new standard of cure and it WILL set the bar very, very high, not just for COVID-19 but for many indications.
The most disappointing thing I heard on the ASM call was that available supply of Lero is still miserably small and supply is being postponed. This wouldn't have happened with participation in OWS but there may have been strings attached to that that Cytodyn didn't want. They charted their own course.
Perhaps England will be the route to better supply or at least financing help - who knows? The Second Wave will have the whole world screaming for supply IMO.
12
